Lilly Announces Changes in Key Leader... ( Lechleiter Aims to Reduce Bureau...)

Lilly Announces Changes in Key Leadership Roles

Date:5/21/2008

Lechleiter Aims to Reduce Bureaucracy, Streamline Decision Making

INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced changes across its executive leadership structure as the company continues to position itself to compete and win in a challenging business environment.

"Earlier this year I asked each of our senior leaders to look closely at their respective areas to determine if they were optimally structured to meet the demands of our business and our company goals," said John C. Lechleiter, Ph.D., who assumed the role of Lilly president and chief executive officer on April 1, 2008. "As a result of this thorough review, we are implementing a number of changes that will minimize bureaucracy by reducing the number of layers of management, will speed decision-making by clarifying roles and accountabilities, and will allow us to respond more quickly to critical business needs."

Continued Lechleiter, "These changes represent important elements in enabling the implementation of our strategy. In some cases, they have resulted in staffing changes, with new leaders in key roles."

Changes in management structure and key leadership roles across several areas of the company have recently been announced to employees, with most changes becoming effective during the second quarter. Highlights of the executive level changes include the following:

Lilly Research Laboratories (LRL):

The executive leadership structure of the company's research and development organization, Lilly Research Laboratories (LRL), will undergo changes designed to reduce bureaucracy and clarify accountabilities. Two senior leaders in the LRL organization have announced their intent to depart fro
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients

Post Your Comments:

Lilly Announces Changes in Key Leader...( Lechleiter Aims to Reduce Bureau...),Health